A prospective, multicentre, randomized, open- label, 3-parallel groups, phase 2 study to evaluate efficacy and safety of masitinib at 9 mg/kg/day in combination with oxaliplatin, 5‐fluorouracil (5-FU) and folinic acid (FOLFOX) or in combination with irinotecan, 5-fluorouracil (5-FU) and folinic acid (FOLFIRI) or in combination with gemcitabine (GEM) in the treatment of patients with metastatic colorectal cancer in progression after a first line treatment.

Trial Profile

A prospective, multicentre, randomized, open- label, 3-parallel groups, phase 2 study to evaluate efficacy and safety of masitinib at 9 mg/kg/day in combination with oxaliplatin, 5‐fluorouracil (5-FU) and folinic acid (FOLFOX) or in combination with irinotecan, 5-fluorouracil (5-FU) and folinic acid (FOLFIRI) or in combination with gemcitabine (GEM) in the treatment of patients with metastatic colorectal cancer in progression after a first line treatment.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 25 Jun 2015

At a glance

  • Drugs Masitinib (Primary) ; Fluorouracil; Folinic acid; Gemcitabine; Irinotecan; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Jun 2015 Status changed from recruiting to completed, according to an AB Science media release.
    • 02 Jun 2015 Safety results in masitinib + FOLFIRI treatment group presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 18 May 2015 According to an AB Science media release, data from this study will be presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top